Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shannon Smiley (NPI 1891715942)

Field	Value
Entity Type	Individual
Organization	Shannon Smiley
Address	3851 Piper Street
City	Anchorage
State	AK
ZIP	99508
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 20, 2006

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

Specialty mix and service model: Taxonomy listed as Hematology & Oncology Physician and the revenue mix is dominated by high-cost oncology injectables and chemotherapy administration codes, consistent with an oncology infusion practice that delivers systemic cancer therapies in-office. The leading codes — J9271 and J0897 — are both injectable biologics used in oncology/supportive care, while numerous chemotherapy administration codes (96413, 96401, 96417, 96375) and lab panels (80053, 85025) indicate on-site infusion and monitoring capabilities.

Extreme revenue concentration in a few drugs: The provider’s top three Medicare codes account for 81.6% of total Medicare revenue, with J9271 generating $851.4K (53.7%), J0897 generating $312.4K (19.7%), and 99214 generating $130.6K (8.2%). This concentration shows the practice’s financial reliance on a small set of high-revenue biologic therapies and related evaluation visits.

Payer mix is effectively single-payer Medicare: Lifetime Medicare revenue of $1.6M contrasts with Medicaid billing listed as none, meaning the provider operates with negligible or no Medicaid volume on file and is functionally Medicare-dependent for public-payer revenue. Analysts should treat this profile as Medicare-centric when benchmarking utilization, reimbursement risk, and population access.

Competitive standing on key immunotherapy and supportive-care drugs: J0897 ranks #437 of 10057 providers nationally (96th percentile) and is described as notably above typical national volume, indicating this provider is a high-volume denosumab prescriber relative to peers. 99214 ranks #10247 of 479517 providers nationally (98th percentile) and is also described as notably above typical national volume, signaling above-average office E&M activity for an established-patient oncology population.

Pembrolizumab volume is substantial but not an extreme outlier: J9271 accounts for the single largest share of revenue at $851.4K and ranks #406 of 1841 providers nationally (77th percentile), where it is labeled typical, unremarkable volume. In practical terms, pembrolizumab is the dominant revenue driver but the provider’s national volume for this specific drug does not appear unusually high relative to other oncology providers.

Operational intensity reflected in procedure and lab mix: The provider billed 477 claims for 96413 ($55.8K) and 459 claims for 96375 ($6.9K), alongside 1.3K claims for 80053 ($13.3K) and 1.4K claims for 85025 ($11.2K), indicating steady throughput of infusion encounters with concurrent laboratory monitoring. This pattern is consistent with a practice that pairs IV/immunotherapy administration with same-site diagnostic testing and supportive medications.

Tenure and market presence: The NPI was enumerated on 2006-07-20 (~20 years ago), suggesting a long-standing presence in the Anchorage market that may support established referral relationships and operational infrastructure for infusion services. Analysts should factor longevity when assessing network relationships and historical prescribing patterns.

Revenue vulnerability and payer policy exposure: Given that two injectable drugs (J9271 and J0897) drive the majority of Medicare revenue and the top three codes account for 81.6% of Medicare revenue, the practice is exposed to shifts in drug utilization, pricing, biosimilar competition, and Medicare coverage or reimbursement changes for those specific agents. Strategic or contractual changes by payers affecting these drugs could materially alter the provider’s revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,800	$40	$851.4K
J0897	Injection, denosumab, 1 mg	16,440	$20	$312.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,050	$130	$130.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$120	$55.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	500	$80	$40.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	180	$180	$32.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	70	$340	$24.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	280	$80	$23.2K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	80	$220	$16.6K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	110	$130	$13.8K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

Shannon Smiley — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	10	13,300	$40	$609.5K
J0897	1	30	2,700	$20	$82.7K
J2506	1	10	440	$80	$36.8K
96413	5	20	230	$110	$30.2K
J1454	1	10	50	$350	$18.4K
99214	8	1,210	90	$100	$16.2K
J9217	9	20	100	$130	$14.8K
99232	278	280	80	$80	$14K
99215	39	400	40	$150	$11K
99213	125	1,290	70	$70	$8.5K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Shannon Smiley, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Natalie Wallace	AK	Hematology & Oncology Physician	$1.2M	$0
Theodore Kim	AK	Hematology & Oncology Physician	$1.2M	$0
Katmai Oncology Group, LLC	AK	Medical Oncology Physician	$0	$872.8K
Ellen Chirichella	AK	Hematology & Oncology Physician	$855.8K	$0
Kendal Webb	AK	Hematology & Oncology Physician	$292.4K	$0
Mary Klix	AK	Hematology & Oncology Physician	$113.4K	$0
Terri Tope	AK	Nurse Practitioner	$48.3K	$0
Charles Buess	AK	Hematology & Oncology Physician	$4.2K	$0

Nearby Providers

Other providers in the same ZIP code as Shannon Smiley, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$397.1M
Providence Health & Services Washington	AK	General Acute Care Hospital	$0	$161.5M
Southcentral Foundation	AK	Community Health Clinic/Center	$0	$130.3M
Alaska Native Tribal Health Consortium	AK	Transportation Broker	$0	$65.5M
The Arc Of Anchorage	AK	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$50.8M
Good Samaritan Care Services	AK	In Home Supportive Care Agency	$0	$46.1M
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$33.1M
Galen Hospital Alaska, Inc.	AK	General Acute Care Hospital	$0	$31.8M
Anchorage Community Mental Health	AK	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$31.7M
Patient Housing At Anmc	AK	General Acute Care Hospital	$0	$31M

Shannon Smiley — Billing Profile & Reimbursement Data

Sign up for Shannon Smiley — Billing Profile & Reimbursement Data policy alerts

Shannon Smiley — Billing Profile & Reimbursement Data

Sign up for Shannon Smiley — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References